<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Long-term survivors after autologous peripheral blood stem cell transplantation (APBSCT) for <z:hpo ids='HP_0002665'>lymphoma</z:hpo> or <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> are known to have a high risk of developing <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), but the risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> is not clear for patients transplanted for <z:mp ids='MP_0009440'>myeloma</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>We reviewed the outcomes for 82 <z:mp ids='MP_0009440'>myeloma</z:mp> patients who underwent APBSCT at our center </plain></SENT>
<SENT sid="2" pm="."><plain>The group included 47 men and 35 women of median age 56 years (range: 37-74 years) </plain></SENT>
<SENT sid="3" pm="."><plain>Median time from diagnosis to APBSCT was 8.2 months (range: 2.6-86.1 months) </plain></SENT>
<SENT sid="4" pm="."><plain>Before coming to transplantation, 28% had received oral melphalan (MEL), 98% received other chemotherapy and 34% received radiation </plain></SENT>
<SENT sid="5" pm="."><plain>A single APBSCT was provided for 68, and 32% underwent APBSCT more than once </plain></SENT>
<SENT sid="6" pm="."><plain>High-dose MEL alone was used as the preparative regimen for 83%, and the remainder received at least one APBSCT with a more intensive preparative regimen </plain></SENT>
<SENT sid="7" pm="."><plain>Ten patients (12%) developed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>The 5-year cumulative incidence is 18% (95% confidence interval, 9-30%) </plain></SENT>
<SENT sid="9" pm="."><plain>There were no demographic factors associated with an increased risk of developing <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Median survival after the diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> was 18 months </plain></SENT>
<SENT sid="11" pm="."><plain>There is a relatively high risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> after APBSCT for <z:mp ids='MP_0009440'>myeloma</z:mp>, and optimal therapy has not been established for these patients </plain></SENT>
</text></document>